Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Eur J Clin Nutr ; 64(7): 714-9, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20517325

RESUMEN

OBJECTIVES: We investigated the correlation between Japanese apricot (JA) intake and Helicobacter pylori-related chronic atrophic gastritis (CAG). METHODS: A questionnaire was administered and serum anti-H. pylori IgG antibodies measured in 1358 asymptomatic adults. The subjects were divided into high-intake and low-intake groups. Histological and serological evaluation of H. pylori-related CAG was performed in 68 non-elderly volunteers. RESULTS: The H. pylori-negative rate did not differ significantly between the high-intake and low-intake groups. Mean antibody titers were lower in the high-intake group, but the difference was not significant. There was no significant difference in the rate of H. pylori infection on the basis of JA intake when subjects were stratified by age. Among H. pylori-positive non-elderly subjects, antibody titers were significantly lower in the high-intake group (P=0.041). Endoscopic tissue biopsy from the 68 volunteers showed less H. pylori bacterial load and mononuclear infiltration irrespective of gastric site in the high-intake group. In the high-intake group, antral neutrophil infiltration was significantly less pronounced and corporal atrophy was less extensive. Serological evaluation using serum PG levels also confirmed these histopathological data. CONCLUSIONS: Our findings strongly indicate a preventive effect of JA intake on CAG by inhibiting H. pylori infection and reducing active mucosal inflammation.


Asunto(s)
Dieta , Gastritis/prevención & control , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Preparaciones de Plantas/uso terapéutico , Prunus , Estómago/efectos de los fármacos , Adulto , Anciano , Anticuerpos/sangre , Enfermedad Crónica , Relación Dosis-Respuesta a Droga , Femenino , Frutas , Gastritis/inmunología , Gastritis/microbiología , Infecciones por Helicobacter/epidemiología , Infecciones por Helicobacter/inmunología , Humanos , Masculino , Persona de Mediana Edad , Neutrófilos/efectos de los fármacos , Pepsinógeno C/sangre , Preparaciones de Plantas/farmacología , Prevalencia , Estómago/inmunología , Estómago/microbiología , Encuestas y Cuestionarios
2.
Arterioscler Thromb Vasc Biol ; 21(11): 1857-63, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11701478

RESUMEN

- Glycoprotein VI (GPVI) is a platelet-specific receptor for collagen that figures prominently in signal transduction. An addition to binding to type I and III collagens, GPVI is also bound specifically by collagen-related peptide and convulxin (CVX), a snake venom protein. We developed a quantitative assay of platelet GPVI in which biotin-conjugated CVX binds selectively to GPVI in separated total platelet proteins by a ligand blot procedure. Using this approach, we have documented a 5-fold range in platelet GPVI content among 23 normal healthy subjects. In addition, we have determined that CVX-induced or collagen-related peptide-induced prothrombinase activity is directly proportional to the platelet content of GPVI. A statistically significant correlation was observed at 2 CVX concentrations: 14.7 ng/mL (R(2)=0.854 and P<0.001, n=11) and 22 ng/mL (R(2)=0.776 and P<0.001, n=12). In previous studies, we established a similar range of expression of the integrin collagen receptor alpha(2)beta(1) on platelets of normal subjects. Among 15 donors, there is a direct correlation between platelet alpha(2)beta(1) density and GPVI content (R(2)=0.475 and P=0.004). In view of the well-documented association of GPVI with platelet procoagulant activity, this study suggests that the variation in GPVI content is a potential risk factor that may predispose individuals to hemorrhagic or thromboembolic disorders.


Asunto(s)
Plaquetas/química , Plaquetas/enzimología , Lectinas Tipo C , Glicoproteínas de Membrana Plaquetaria/análisis , Glicoproteínas de Membrana Plaquetaria/fisiología , Tromboplastina/metabolismo , Venenos de Crotálidos/metabolismo , Venenos de Crotálidos/farmacología , ADN Complementario , Electroforesis en Gel de Poliacrilamida , Hemorragia/etiología , Humanos , Integrinas/metabolismo , Activación Plaquetaria/efectos de los fármacos , Glicoproteínas de Membrana Plaquetaria/genética , Receptores de Colágeno , Trombosis/etiología
3.
Thromb Haemost ; 86(1): 386-94, 2001 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-11487028

RESUMEN

Regulation of hemostasis and thrombosis involves numerous plasma factors that contribute to procoagulant and anticoagulant pathways. Lipid-containing surfaces provide sites where both procoagulant and anticoagulant enzymes, cofactors and substrates are assembled to express their activities. Plasma and lipoproteins can contribute to either procoagulant or anticoagulant reactions. Procoagulant lipids/lipoproteins include triglyceride-rich particles in plasma and oxidized low density lipoprotein (LDL) which can accelerate activation of prothrombin, factor X and factor VII. Potentially anticoagulant lipids and lipoproteins, each of which enhances inactivation of factor Va by activated protein C, include phosphatidylethanolamine, cardiolipin, the neutral glycosphingolipids glucosylceramide and Gb3 ceramide (CD77), and high density lipoprotein (HDL). Remarkably, treatment of hyperlipidemia with statins not only lowers lipids but also provides antithrombotic effects whose mechanisms remain to be clarified. We hypothesize that procoagulant and anticoagulant lipids and lipoproteins in plasma may contribute to a Yin-Yang balance that helps influence the up-regulation and down-regulation of thrombin generation.


Asunto(s)
Hemostasis/efectos de los fármacos , Lipoproteínas/sangre , Lipoproteínas/farmacología , Trombosis/etiología , Animales , Factores de Coagulación Sanguínea/efectos de los fármacos , Humanos , Protrombina/efectos de los fármacos , Protrombina/metabolismo , Trombosis/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA